Cargando…
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic abil...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166538/ https://www.ncbi.nlm.nih.gov/pubmed/27994665 http://dx.doi.org/10.7150/jca.15758 |
_version_ | 1782483048137228288 |
---|---|
author | Pu, Weilin Geng, Xin Chen, Sidi Tan, Lixing Tan, Yulong Wang, An Lu, Zhouyi Guo, Shicheng Chen, Xiaofeng Wang, Jiucun |
author_facet | Pu, Weilin Geng, Xin Chen, Sidi Tan, Lixing Tan, Yulong Wang, An Lu, Zhouyi Guo, Shicheng Chen, Xiaofeng Wang, Jiucun |
author_sort | Pu, Weilin |
collection | PubMed |
description | Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma. |
format | Online Article Text |
id | pubmed-5166538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-51665382016-12-19 Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma Pu, Weilin Geng, Xin Chen, Sidi Tan, Lixing Tan, Yulong Wang, An Lu, Zhouyi Guo, Shicheng Chen, Xiaofeng Wang, Jiucun J Cancer Research Paper Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma. Ivyspring International Publisher 2016-11-25 /pmc/articles/PMC5166538/ /pubmed/27994665 http://dx.doi.org/10.7150/jca.15758 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Pu, Weilin Geng, Xin Chen, Sidi Tan, Lixing Tan, Yulong Wang, An Lu, Zhouyi Guo, Shicheng Chen, Xiaofeng Wang, Jiucun Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title | Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title_full | Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title_fullStr | Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title_full_unstemmed | Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title_short | Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma |
title_sort | aberrant methylation of cdh13 can be a diagnostic biomarker for lung adenocarcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166538/ https://www.ncbi.nlm.nih.gov/pubmed/27994665 http://dx.doi.org/10.7150/jca.15758 |
work_keys_str_mv | AT puweilin aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT gengxin aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT chensidi aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT tanlixing aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT tanyulong aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT wangan aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT luzhouyi aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT guoshicheng aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT chenxiaofeng aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma AT wangjiucun aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma |